What are the recommended treatments for non‑alcoholic steatohepatitis (NASH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment for NASH

Weight loss through caloric restriction is the cornerstone of NASH treatment, with 7-10% body weight reduction required to improve disease activity and fibrosis, and >10% weight loss associated with NASH resolution and fibrosis improvement 1.

Lifestyle Modification: First-Line Therapy

Weight reduction is fundamental and shows a dose-response relationship with histological improvement:

  • 5% weight loss: Improves steatosis
  • 7-10% weight loss: Required to positively affect NASH activity score and fibrosis
  • >10% weight loss: Associated with NASH resolution and one-stage fibrosis improvement 1

Exercise Requirements

Implement 150-300 minutes of moderate-intensity exercise or 75-150 minutes of vigorous-intensity exercise per week 2. Physical activity decreases aminotransferases and steatosis even without significant weight loss.

Dietary Approach

The Mediterranean diet is the most widely recommended dietary pattern for NAFLD due to its documented potential to reduce hepatic fat content and improve cardiovascular risk 1. Referral to weight management services should be considered when weight loss goals are not achieved through office-based efforts.

Pharmacological Treatment

For Patients WITHOUT Diabetes

Vitamin E (800 IU/day) is recommended for biopsy-proven NASH without type 2 diabetes, showing improved steatohepatitis in large randomized trials 2. A retrospective study demonstrated transplant-free survival and lower rates of hepatic decompensation among vitamin E users with advanced fibrosis or cirrhosis.

For Patients WITH Diabetes

Prioritize GLP-1 receptor agonists and pioglitazone as they have proven efficacy for both NASH and diabetes management 2:

GLP-1 Receptor Agonists:

  • Semaglutide (0.4 mg/day) achieved NASH resolution without worsening fibrosis in 59% of patients versus 17% with placebo (P < .001) in 320 patients with biopsy-proven NASH 2
  • Liraglutide showed reversal of steatohepatitis and amelioration of fibrosis progression after 12 months 2
  • Common adverse effects include nausea, constipation, and vomiting

Pioglitazone:

  • Five RCTs demonstrated improvement in liver histology, primarily steatohepatitis 2
  • Meta-analysis showed resolution of NASH (odds ratio 3.22) and reversal of advanced fibrosis (odds ratio 3.15) 2
  • Associated with average weight gain of 2.7%, which can be prevented with nutritional counseling or combining with SGLT2 inhibitors or GLP-1RAs
  • Contraindicated in decompensated cirrhosis 2

SGLT2 Inhibitors:

  • Reduce steatosis by approximately 20% but effects on liver histology remain unknown 2
  • Particularly beneficial for patients with congestive heart failure or chronic kidney disease

Medications to Avoid

  • Metformin: No major effect on steatohepatitis in RCTs 2
  • DPP-IV inhibitors: Consistently negative in RCTs 2

Bariatric Surgery

Refer for bariatric surgery consideration in NASH patients with obesity who meet national eligibility criteria 1. This is particularly important when dietary goals have not been achieved.

Evidence supporting bariatric surgery:

  • 85% NASH resolution rate at one year post-surgery in prospective study of 109 individuals 1
  • Meta-analysis showed improvement in steatosis (88%), steatohepatitis (59%), and fibrosis (30%) 1
  • Improves overall mortality from cardiovascular and malignant causes
  • Can be performed safely even in patients with cirrhosis 1

Risk Stratification for Treatment Intensity

High-Risk Patients (FIB-4 >2.67, LSM >12.0 kPa, or significant fibrosis on biopsy)

These patients require:

  • Hepatologist-led multidisciplinary team management 2
  • Aggressive lifestyle changes with structured weight loss programs
  • Greater use of formal weight loss programs and anti-obesity medications
  • Consideration of bariatric surgery in appropriate candidates
  • Preference for diabetes medications with known NASH efficacy (GLP-1RAs, pioglitazone)
  • Regular surveillance for cirrhosis complications and HCC 1

Lower-Risk Patients

  • Focus on lifestyle modification and cardiovascular risk factor management
  • Statins are safe and recommended 2
  • Standard diabetes management following current guidelines

Critical Caveats

  • No FDA-approved medications specifically for NASH exist 2, though multiple agents are in phase 3 trials
  • Pioglitazone and vitamin E remain off-label for NASH treatment 3
  • Statins can be prescribed to patients with F2-F3 fibrosis and Child A or B cirrhosis 2
  • Treatment decisions should prioritize medications that address both NASH and associated cardiometabolic comorbidities to impact long-term morbidity and mortality 2

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.